Identification

Name
Oxprenolol
Accession Number
DB01580
Type
Small Molecule
Groups
Approved
Description

A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.

Structure
Thumb
Synonyms
  • Oxprenololum
Product Ingredients
IngredientUNIICASInChI Key
Oxprenolol hydrochlorideF4XSI7SNIU6452-73-9COAJXCLTPGGDAJ-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Slow Trasicor Tab 160mgTablet, extended release160 mgOralNovartis1981-12-312005-08-02Canada
Slow Trasicor Tab 80mgTablet, extended release80 mgOralNovartis1981-12-312005-08-02Canada
Trasicor Tab 20mgTablet20 mgOralNovartis1980-12-311999-08-04Canada
Trasicor Tab 40mgTablet40 mgOralNovartis1980-12-312008-01-22Canada
Trasicor Tab 80mgTablet80 mgOralNovartis1980-12-312009-02-25Canada
International/Other Brands
Trasacor / Trasicor
Categories
UNII
519MXN9YZR
CAS number
6452-71-7
Weight
Average: 265.348
Monoisotopic: 265.167793607
Chemical Formula
C15H23NO3
InChI Key
CEMAWMOMDPGJMB-UHFFFAOYSA-N
InChI
InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3
IUPAC Name
1-[2-(prop-2-en-1-yloxy)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=CC=C1OCC=C

Pharmacology

Indication

Used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.

Structured Indications
Not Available
Pharmacodynamics

Oxprenolol is a non-selective beta blocker with some intrinsic sympathomimetic activity. Oxprenolol is a lipophilic beta blocker which passes the blood-brain barrier more easily than water soluble beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than hydrophilic ligands such as atenolol, sotalol and nadolol. Oxprenolol is an potent beta-blocker and should not be administered to asthmatics because it can cause irreversible airway failure and inflammation.

Mechanism of action

Like other beta-adrenergic antagonists, oxprenolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, oxprenolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, oxprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Oxprenolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
UBeta-3 adrenergic receptorNot AvailableHuman
Absorption

Oral bioavailability is 20-70%.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life

1-2 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Oxprenolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Oxprenolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Oxprenolol is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Oxprenolol.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Oxprenolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Oxprenolol.Approved, Experimental, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Aceprometazine.Approved
AcetohexamideOxprenolol may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Acetylcholine.Approved
AcetyldigitoxinOxprenolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinOxprenolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Oxprenolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Oxprenolol.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Adipiplon.Investigational
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Agomelatine.Approved, Investigational
AlaproclateThe serum concentration of Oxprenolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Oxprenolol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Oxprenolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Oxprenolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Oxprenolol.Approved, Vet Approved
AliskirenOxprenolol may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Allopregnanolone.Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Oxprenolol.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Oxprenolol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxprenolol.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Oxprenolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Oxprenolol.Approved
AmbrisentanOxprenolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateOxprenolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental, Investigational
AmifostineOxprenolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amiloride.Approved
AminophyllineOxprenolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Oxprenolol.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amitriptyline.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Oxprenolol.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Oxprenolol.Approved, Illicit
AmodiaquineThe metabolism of Oxprenolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the hypotensive activities of Oxprenolol.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Oxprenolol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Oxprenolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Oxprenolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Oxprenolol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Oxprenolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
ArbutamineOxprenolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Arecoline.Experimental
ArformoterolOxprenolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Oxprenolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Oxprenolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Oxprenolol.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Oxprenolol.Approved
AtenololAtenolol may increase the hypotensive activities of Oxprenolol.Approved
AvanafilAvanafil may increase the antihypertensive activities of Oxprenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Azaperone.Investigational, Vet Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Oxprenolol.Withdrawn
AzelastineOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Azilsartan medoxomil.Approved
BaclofenThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Baclofen.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
BambuterolOxprenolol may decrease the bronchodilatory activities of Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Oxprenolol.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Oxprenolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Oxprenolol.Approved
BenazeprilBenazepril may increase the hypotensive activities of Oxprenolol.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Oxprenolol.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Oxprenolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Oxprenolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Oxprenolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Oxprenolol.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Oxprenolol.Approved
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Oxprenolol.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Benzyl alcohol.Approved
BepridilBepridil may increase the hypotensive activities of Oxprenolol.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Oxprenolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Oxprenolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Oxprenolol.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Oxprenolol.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Oxprenolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Oxprenolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Oxprenolol.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Oxprenolol.Approved, Investigational
BQ-123Oxprenolol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Oxprenolol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Oxprenolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Oxprenolol.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Oxprenolol.Approved, Illicit
BromfenacBromfenac may decrease the antihypertensive activities of Oxprenolol.Approved
BromisovalThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Bromisoval.Experimental
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Brotizolam.Approved, Investigational, Withdrawn
BucillamineBucillamine may decrease the antihypertensive activities of Oxprenolol.Investigational
BucindololOxprenolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Oxprenolol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Oxprenolol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Bumetanide.Approved
BunazosinOxprenolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Oxprenolol.Approved, Investigational
BupranololOxprenolol may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxprenolol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxprenolol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Oxprenolol.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Oxprenolol.Approved, Illicit, Vet Approved
CabergolineOxprenolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Oxprenolol.Experimental
CafedrineOxprenolol may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Canagliflozin.Approved
CandesartanOxprenolol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Oxprenolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Oxprenolol.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Canertinib.Investigational
CaptoprilCaptopril may increase the hypotensive activities of Oxprenolol.Approved
CarbacholThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Carbachol.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxprenolol.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Oxprenolol.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Carbinoxamine.Approved
CarbutamideOxprenolol may increase the hypoglycemic activities of Carbutamide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Oxprenolol.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Carisoprodol.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Oxprenolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Oxprenolol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Oxprenolol.Approved
CarvedilolOxprenolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Oxprenolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
CeliprololOxprenolol may increase the hypotensive activities of Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Cetirizine.Approved
CevimelineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Cevimeline.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Oxprenolol.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxprenolol.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Oxprenolol.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Oxprenolol.Approved
ChloroquineThe metabolism of Oxprenolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Oxprenolol.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Chlorphenamine.Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Oxprenolol.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxprenolol.Approved, Vet Approved
ChlorpropamideOxprenolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Oxprenolol.Approved, Investigational, Withdrawn
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Oxprenolol.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Chlorzoxazone.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Oxprenolol.Approved
CicletanineOxprenolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Oxprenolol.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Oxprenolol.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Oxprenolol.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clemastine.Approved
ClenbuterolOxprenolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Oxprenolol.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Oxprenolol is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clonazepam.Approved, Illicit
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Oxprenolol.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clopenthixol.Experimental
CloranololOxprenolol may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxprenolol.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Oxprenolol.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Oxprenolol.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxprenolol.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Oxprenolol.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Oxprenolol.Vet Approved
CryptenamineCryptenamine may increase the hypotensive activities of Oxprenolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Oxprenolol.Investigational
CyclizineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxprenolol.Approved
CyclopenthiazideOxprenolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Oxprenolol.Approved
CymarinOxprenolol may increase the bradycardic activities of Cymarin.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Cyproheptadine.Approved
D-LimoneneD-Limonene may decrease the antihypertensive activities of Oxprenolol.Investigational
DantroleneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxprenolol.Approved
DapoxetineThe serum concentration of Oxprenolol can be increased when it is combined with Dapoxetine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Oxprenolol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Oxprenolol.Approved
DelaprilOxprenolol may increase the hypotensive activities of Delapril.Experimental
DemecariumDemecarium may increase the bradycardic activities of Oxprenolol.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Deramciclane.Investigational
DeserpidineOxprenolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Oxprenolol.Approved
DesipramineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Desipramine.Approved
DeslanosideOxprenolol may increase the bradycardic activities of Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe serum concentration of Oxprenolol can be increased when it is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dexbrompheniramine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Oxprenolol.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxprenolol.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Oxprenolol.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Oxprenolol.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Oxprenolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Oxprenolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Oxprenolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Diclofenamide.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Diethyl ether.Experimental
diethylnorspermineOxprenolol may increase the hypotensive activities of diethylnorspermine.Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Difenoxin.Approved, Illicit
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Oxprenolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Oxprenolol.Approved
DigitoxinOxprenolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinOxprenolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Oxprenolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Oxprenolol.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Oxprenolol.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Oxprenolol.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Oxprenolol.Experimental, Illicit
DiltiazemDiltiazem may increase the hypotensive activities of Oxprenolol.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dinutuximab.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Oxprenolol.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Oxprenolol.Approved, Illicit
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Oxprenolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Oxprenolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Oxprenolol.Experimental
DixyrazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dixyrazine.Experimental
DobutamineOxprenolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Oxprenolol.Approved
DoramectinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Doramectin.Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Oxprenolol.Approved
DoxazosinOxprenolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Oxprenolol is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved, Illicit
DronedaroneDronedarone may increase the bradycardic activities of Oxprenolol.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Oxprenolol.Experimental, Illicit
DroxicamDroxicam may decrease the antihypertensive activities of Oxprenolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved, Investigational
DuloxetineOxprenolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Oxprenolol.Investigational
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxprenolol.Approved
DyphyllineOxprenolol may decrease the bronchodilatory activities of Dyphylline.Approved
E-6201E-6201 may decrease the antihypertensive activities of Oxprenolol.Investigational
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Oxprenolol.Experimental, Illicit
EchothiophateEchothiophate may increase the bradycardic activities of Oxprenolol.Approved
EcopipamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ecopipam.Investigational
EdrophoniumEdrophonium may increase the bradycardic activities of Oxprenolol.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Efavirenz.Approved, Investigational
EfonidipineOxprenolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Oxprenolol.Approved, Vet Approved
EnalaprilatOxprenolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Oxprenolol.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Oxprenolol.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Entacapone.Approved, Investigational
EpanololOxprenolol may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Oxprenolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Eplerenone.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Oxprenolol.Approved
EprosartanEprosartan may increase the hypotensive activities of Oxprenolol.Approved
Ergoloid mesylateOxprenolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineOxprenolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Oxprenolol.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxprenolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
EthanolOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxprenolol.Approved, Illicit, Withdrawn
EthenzamideEthenzamide may decrease the antihypertensive activities of Oxprenolol.Experimental
EthosuximideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Oxprenolol.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Oxprenolol.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Etizolam.Approved
EtodolacEtodolac may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
EtoperidoneThe serum concentration of Oxprenolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Oxprenolol.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
exisulindexisulind may decrease the antihypertensive activities of Oxprenolol.Investigational
EzogabineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Felbamate.Approved
FelbinacFelbinac may decrease the antihypertensive activities of Oxprenolol.Experimental
FelodipineFelodipine may increase the hypotensive activities of Oxprenolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Oxprenolol.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Oxprenolol.Approved, Illicit, Withdrawn
FenoldopamFenoldopam may increase the hypotensive activities of Oxprenolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Oxprenolol.Approved
FenoterolOxprenolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxprenolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Oxprenolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Oxprenolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Oxprenolol.Experimental
Ferulic acidOxprenolol may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxprenolol.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Oxprenolol.Approved, Investigational
FingolimodOxprenolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Flibanserin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Floctafenine.Approved, Withdrawn
FluanisoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Oxprenolol.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Oxprenolol.Approved, Illicit
FlunixinFlunixin may decrease the antihypertensive activities of Oxprenolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Oxprenolol.Experimental
FluoxetineThe serum concentration of Oxprenolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Oxprenolol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxprenolol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxprenolol.Approved, Illicit
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Oxprenolol.Approved, Investigational
FormoterolOxprenolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Oxprenolol.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fospropofol.Approved, Illicit, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Oxprenolol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Oxprenolol.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Gabapentin Enacarbil.Approved
GalantamineGalantamine may increase the bradycardic activities of Oxprenolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Oxprenolol.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Oxprenolol.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Gepirone.Investigational
GitoformateOxprenolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideOxprenolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideOxprenolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideOxprenolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideOxprenolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneOxprenolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideOxprenolol may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Oxprenolol.Approved, Illicit
GlyburideOxprenolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Oxprenolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Oxprenolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Oxprenolol.Approved
GuanazodineOxprenolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Oxprenolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved, Investigational
GuanoclorOxprenolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzOxprenolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanOxprenolol may increase the hypotensive activities of Guanoxan.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Oxprenolol.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxprenolol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Oxprenolol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Oxprenolol.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Oxprenolol.Approved, Illicit, Investigational
HexamethoniumOxprenolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Oxprenolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Oxprenolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Oxprenolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Oxprenolol.Experimental
HydralazineHydralazine may increase the hypotensive activities of Oxprenolol.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Oxprenolol.Approved, Vet Approved
HydrocodoneOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Oxprenolol.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxprenolol.Approved, Illicit
HydroxychloroquineThe metabolism of Oxprenolol can be decreased when combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Oxprenolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Oxprenolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Oxprenolol.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Oxprenolol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Oxprenolol.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Oxprenolol.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Imipramine.Approved
IndacaterolOxprenolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Oxprenolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Oxprenolol.Approved
IndenololOxprenolol may increase the hypotensive activities of Indenolol.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Indiplon.Investigational
IndobufenIndobufen may decrease the antihypertensive activities of Oxprenolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Oxprenolol.Withdrawn
IndoraminOxprenolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanOxprenolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkOxprenolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Oxprenolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Oxprenolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Oxprenolol.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Oxprenolol.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Oxprenolol.Approved
IsoetarineOxprenolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Oxprenolol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Oxprenolol.Approved, Investigational, Withdrawn
IsoprenalineOxprenolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Oxprenolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Oxprenolol.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Oxprenolol.Experimental
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Oxprenolol.Approved, Vet Approved
KetanserinKetanserin may increase the hypotensive activities of Oxprenolol.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ketobemidone.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Oxprenolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Oxprenolol.Approved
LabetalolOxprenolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineOxprenolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Lamotrigine.Approved, Investigational
Lanatoside COxprenolol may increase the bradycardic activities of Lanatoside C.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Oxprenolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Oxprenolol.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Oxprenolol.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Levocetirizine.Approved
LevodopaOxprenolol may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Oxprenolol.Approved, Investigational
LevomilnacipranThe serum concentration of Oxprenolol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Oxprenolol.Approved
LevosalbutamolOxprenolol may decrease the bronchodilatory activities of Levosalbutamol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Oxprenolol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Oxprenolol.Approved, Vet Approved
LinsidomineOxprenolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Oxprenolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Oxprenolol.Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Oxprenolol.Approved
LobelineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Lobeline.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Lofentanil.Illicit
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Oxprenolol.Experimental
LoprazolamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxprenolol.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Lormetazepam.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Oxprenolol.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxprenolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Oxprenolol.Approved
MacitentanOxprenolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Oxprenolol.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved, Vet Approved
MalathionMalathion may increase the bradycardic activities of Oxprenolol.Approved, Investigational
ManidipineOxprenolol may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Maprotiline.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Oxprenolol.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Mebicar.Experimental
MecamylamineMecamylamine may increase the hypotensive activities of Oxprenolol.Approved
MeclizineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Meclizine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Oxprenolol.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Medetomidine.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Oxprenolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Oxprenolol.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Oxprenolol.Approved, Nutraceutical, Vet Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Oxprenolol.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Melperone.Approved, Investigational
MemantineMemantine may increase the bradycardic activities of Oxprenolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Oxprenolol.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxprenolol.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Meptazinol.Experimental
MesalazineMesalazine may decrease the antihypertensive activities of Oxprenolol.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Oxprenolol.Approved, Investigational
MetahexamideOxprenolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Oxprenolol.Investigational, Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Metaxalone.Approved
MethacholineOxprenolol may increase the bronchoconstrictory activities of Methacholine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Oxprenolol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Oxprenolol.Approved, Illicit
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Oxprenolol.Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxprenolol.Approved
MethoserpidineOxprenolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Oxprenolol.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methyclothiazide.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Oxprenolol.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methylecgonine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Oxprenolol.Approved, Investigational
MethylergometrineOxprenolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Oxprenolol.Approved
MetildigoxinOxprenolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololMetipranolol may increase the hypotensive activities of Oxprenolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Oxprenolol.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Oxprenolol.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Oxprenolol.Approved, Investigational
MetyrosineOxprenolol may increase the sedative activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Oxprenolol.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxprenolol.Approved, Illicit
MidodrineOxprenolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Oxprenolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Oxprenolol.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved, Investigational
MinoxidilMinoxidil may increase the hypotensive activities of Oxprenolol.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Oxprenolol.Investigational
MirtazapineOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Oxprenolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Oxprenolol.Approved
MoexiprilMoexipril may increase the hypotensive activities of Oxprenolol.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Oxprenolol.Experimental
MolindoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Molindone.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Oxprenolol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Oxprenolol.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Oxprenolol.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved, Investigational
MuzolimineOxprenolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Oxprenolol.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Oxprenolol.Approved
NadololNadolol may increase the hypotensive activities of Oxprenolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Oxprenolol.Approved
NaftopidilOxprenolol may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Oxprenolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Oxprenolol.Approved, Vet Approved
NebivololOxprenolol may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Oxprenolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Oxprenolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Oxprenolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Oxprenolol.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Oxprenolol.Approved
NicorandilNicorandil may increase the hypotensive activities of Oxprenolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Oxprenolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Oxprenolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Oxprenolol.Approved
NiguldipineOxprenolol may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineOxprenolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Oxprenolol.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Oxprenolol.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Oxprenolol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Oxprenolol.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Oxprenolol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Oxprenolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Oxprenolol.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Oxprenolol.Approved, Vet Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Nortriptyline.Approved
ObinutuzumabOxprenolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Oxprenolol.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxprenolol.Approved, Investigational
OleandrinOxprenolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Oxprenolol.Approved, Investigational
OlodaterolOxprenolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Olopatadine.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Oxprenolol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Oxprenolol.Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Oxprenolol.Approved
OpiumThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Opium.Approved, Illicit
OrciprenalineOxprenolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Oxprenolol.Vet Approved
OrphenadrineOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Osanetant.Investigational
OuabainOxprenolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Oxprenolol.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Oxprenolol.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Oxethazaine.Approved, Investigational
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxprenolol.Approved, Illicit, Investigational
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Oxprenolol.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Oxprenolol.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Paclitaxel.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
PapaverineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Papaverine.Approved
ParaldehydeOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParaoxonParaoxon may increase the bradycardic activities of Oxprenolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Oxprenolol.Approved
PargylinePargyline may increase the hypotensive activities of Oxprenolol.Approved
ParoxetineThe serum concentration of Oxprenolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Oxprenolol.Investigational
PenbutololPenbutolol may increase the hypotensive activities of Oxprenolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxprenolol.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Oxprenolol.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Oxprenolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Oxprenolol.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
PerazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Perazine.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Oxprenolol.Approved
PerospironeThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Oxprenolol.Approved
PeruvosideOxprenolol may increase the bradycardic activities of Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxprenolol.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Oxprenolol.Approved
PhenibutThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Phenibut.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Oxprenolol.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Oxprenolol.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Oxprenolol.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Phenoxyethanol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Oxprenolol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Oxprenolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Oxprenolol.Approved, Vet Approved
PhenytoinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Phenytoin.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Oxprenolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Oxprenolol.Approved
PinacidilPinacidil may increase the hypotensive activities of Oxprenolol.Withdrawn
PindololPindolol may increase the hypotensive activities of Oxprenolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pipotiazine.Approved, Investigational
PirbuterolOxprenolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Piritramide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Oxprenolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Oxprenolol.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Oxprenolol.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pizotifen.Approved
Platelet Activating FactorOxprenolol may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Oxprenolol.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pomalidomide.Approved
PramipexoleOxprenolol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pramocaine.Approved
PranoprofenPranoprofen may decrease the antihypertensive activities of Oxprenolol.Experimental, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Prazepam.Approved, Illicit
PrazosinOxprenolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Oxprenolol.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Oxprenolol.Approved
PrimaquineThe metabolism of Oxprenolol can be decreased when combined with Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Oxprenolol.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Oxprenolol.Approved
ProcaterolOxprenolol may decrease the bronchodilatory activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxprenolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Oxprenolol.Experimental
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Oxprenolol.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Promethazine.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
PropafenoneThe serum concentration of Oxprenolol can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Oxprenolol.Approved, Vet Approved
PropericiazinePropericiazine may increase the hypotensive activities of Oxprenolol.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Oxprenolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Oxprenolol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Propoxycaine.Approved
PropranololPropranolol may increase the hypotensive activities of Oxprenolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Oxprenolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Oxprenolol.Experimental
ProscillaridinOxprenolol may increase the bradycardic activities of Proscillaridin.Experimental
ProtriptylineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Oxprenolol is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Oxprenolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Oxprenolol.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Oxprenolol.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Oxprenolol.Approved
QuinaprilQuinapril may increase the hypotensive activities of Oxprenolol.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Oxprenolol.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ramelteon.Approved, Investigational
RamiprilRamipril may increase the hypotensive activities of Oxprenolol.Approved
RasagilineRasagiline may increase the hypotensive activities of Oxprenolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Oxprenolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Oxprenolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Oxprenolol.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxprenolol.Approved, Withdrawn
RescinnamineOxprenolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Oxprenolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Oxprenolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Oxprenolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Oxprenolol can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Oxprenolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Oxprenolol.Investigational
RiociguatOxprenolol may increase the hypotensive activities of Riociguat.Approved
RisperidoneOxprenolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ritanserin.Investigational
RitodrineOxprenolol may decrease the bronchodilatory activities of Ritodrine.Approved, Investigational
RituximabOxprenolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineOxprenolol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Oxprenolol.Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Romifidine.Vet Approved
RopiniroleOxprenolol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxprenolol.Approved
RotigotineOxprenolol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Oxprenolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Oxprenolol.Withdrawn
SalbutamolOxprenolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Oxprenolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Oxprenolol.Approved, Vet Approved
SalmeterolOxprenolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Oxprenolol.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Oxprenolol.Experimental
ScopolamineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxprenolol.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Oxprenolol.Approved, Investigational, Vet Approved
SelexipagOxprenolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Oxprenolol.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Sepranolone.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Oxprenolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Oxprenolol.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Oxprenolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Oxprenolol.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Oxprenolol.Approved, Investigational
SilodosinOxprenolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanOxprenolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
SotalolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Sotalol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Oxprenolol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Spironolactone.Approved
SRT501SRT501 may decrease the antihypertensive activities of Oxprenolol.Investigational
StiripentolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxprenolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Oxprenolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Oxprenolol.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxprenolol.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Sultopride.Experimental
SuprofenSuprofen may decrease the antihypertensive activities of Oxprenolol.Approved, Withdrawn
SuvorexantOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Oxprenolol.Experimental
TacrineTacrine may increase the bradycardic activities of Oxprenolol.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Oxprenolol.Approved, Investigational
TalinololOxprenolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinOxprenolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Oxprenolol.Investigational
TasimelteonThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tasimelteon.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Oxprenolol.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxprenolol.Approved
TemocaprilOxprenolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Oxprenolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Oxprenolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Oxprenolol.Vet Approved
TerazosinOxprenolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineOxprenolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Oxprenolol.Approved
TerlipressinOxprenolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetrodotoxin.Investigational
ThalidomideOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineOxprenolol may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineOxprenolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Oxprenolol.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Oxprenolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Oxprenolol.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Oxprenolol.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Oxprenolol.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Oxprenolol.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Oxprenolol.Approved
TiagabineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tiapride.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Oxprenolol.Approved
TiboloneOxprenolol may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenOxprenolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tilidine.Experimental
TimololTimolol may increase the hypotensive activities of Oxprenolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Oxprenolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
TolazamideOxprenolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Oxprenolol.Approved, Vet Approved
TolbutamideOxprenolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Oxprenolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Oxprenolol.Approved
TolonidineOxprenolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Oxprenolol.Approved
TopiramateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Topiramate.Approved
TorasemideTorasemide may increase the hypotensive activities of Oxprenolol.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxprenolol.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Oxprenolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxprenolol.Approved
TravoprostTravoprost may increase the hypotensive activities of Oxprenolol.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Oxprenolol.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Oxprenolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Oxprenolol.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Oxprenolol.Experimental
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tricaine methanesulfonate.Vet Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Oxprenolol.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Oxprenolol.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxprenolol.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Oxprenolol.Approved, Vet Approved
TrimazosinOxprenolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Oxprenolol.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Triprolidine.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Oxprenolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Oxprenolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Oxprenolol.Approved, Investigational
UnoprostoneOxprenolol may increase the hypotensive activities of Unoprostone.Approved
UrapidilOxprenolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Oxprenolol.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Oxprenolol.Approved, Investigational
ValsartanValsartan may increase the hypotensive activities of Oxprenolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Oxprenolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Oxprenolol can be increased when it is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Vigabatrin.Approved
VilanterolOxprenolol may decrease the bronchodilatory activities of Vilanterol.Approved
VincamineOxprenolol may increase the hypotensive activities of Vincamine.Experimental
VinpocetineOxprenolol may increase the hypotensive activities of Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Xenon.Experimental
XipamideOxprenolol may increase the hypotensive activities of Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Xylazine.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
YohimbineThe therapeutic efficacy of Oxprenolol can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Oxprenolol.Approved, Illicit, Investigational
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ziconotide.Approved
ZileutonZileuton may decrease the antihypertensive activities of Oxprenolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Oxprenolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Oxprenolol.Approved
ZofenoprilOxprenolol may increase the hypotensive activities of Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Zolazepam.Vet Approved
ZolpidemOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Oxprenolol.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Oxprenolol.Approved
ZotepineThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Oxprenolol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Take without regard to meals.

References

General References
  1. McDevitt DG: Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. Eur Heart J. 1987 Dec;8 Suppl M:9-14. [PubMed:2897304]
External Links
Human Metabolome Database
HMDB15520
PubChem Compound
4631
PubChem Substance
46508996
ChemSpider
4470
BindingDB
50240370
ChEBI
91704
ChEMBL
CHEMBL546
Therapeutic Targets Database
DAP000485
PharmGKB
PA10284
Wikipedia
Oxprenolol
ATC Codes
C07CA02 — Oxprenolol and other diureticsC07BA02 — Oxprenolol and thiazidesC07AA02 — Oxprenolol

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, extended releaseOral160 mg
Tablet, extended releaseOral80 mg
TabletOral20 mg
TabletOral40 mg
TabletOral80 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.10HANSCH,C ET AL. (1995)
Caco2 permeability-4.68ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.68 mg/mLALOGPS
logP2.44ALOGPS
logP2.17ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area50.72 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity76 m3·mol-1ChemAxon
Polarizability30.31 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9817
Blood Brain Barrier-0.9759
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.6618
P-glycoprotein inhibitor INon-inhibitor0.5567
P-glycoprotein inhibitor IINon-inhibitor0.8945
Renal organic cation transporterNon-inhibitor0.8698
CYP450 2C9 substrateNon-substrate0.8122
CYP450 2D6 substrateNon-substrate0.5424
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9209
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8958
Ames testNon AMES toxic0.9367
CarcinogenicityNon-carcinogens0.9206
BiodegradationNot ready biodegradable0.9593
Rat acute toxicity2.5730 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9351
hERG inhibition (predictor II)Non-inhibitor0.7501
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-006t-7920000000-1fed9f62e7ece1c8e951
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-3090000000-9ca7ccd0c0daba3c3040
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9110000000-b81a2c636a97b7a75df0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-9000000000-996746df1ffa4553b2db
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05fr-9000000000-cc715f4401a8ea6f3c13
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05fr-9000000000-7a6e78af4d59990c16da
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ab9-9000000000-986953ff107cdee4fc24

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenoxy compound / Phenol ether / Alkyl aryl ether / Monocyclic benzene moiety / 1,2-aminoalcohol / Secondary alcohol / Secondary aliphatic amine / Secondary amine / Ether / Organic nitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Campbell CA, Parratt JR, Kane KA, Bullock G: Effects of prolonged administration of oxprenolol on severity of ischaemic arrhythmias, enzyme leakage, infarct size, and intracellular cardiac muscle action potentials. J Cardiovasc Pharmacol. 1984 May-Jun;6(3):369-77. [PubMed:6202960]
  4. Lemmer B: [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)]. Herz. 1982 Jun;7(3):168-78. [PubMed:6124492]
  5. Abrahamsson T: The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat. Br J Pharmacol. 1986 Apr;87(4):657-64. [PubMed:2871880]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Sekut L, Champion BR, Page K, Menius JA Jr, Connolly KM: Anti-inflammatory activity of salmeterol: down-regulation of cytokine production. Clin Exp Immunol. 1995 Mar;99(3):461-6. [PubMed:7882570]
  4. Fujita H, Tanaka J, Maeda N, Sakanaka M: Adrenergic agonists suppress the proliferation of microglia through beta 2-adrenergic receptor. Neurosci Lett. 1998 Feb 6;242(1):37-40. [PubMed:9509999]
  5. Prinz M, Hausler KG, Kettenmann H, Hanisch U: beta-adrenergic receptor stimulation selectively inhibits IL-12p40 release in microglia. Brain Res. 2001 Apr 27;899(1-2):264-70. [PubMed:11311890]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name
ADRB3
Uniprot ID
P13945
Uniprot Name
Beta-3 adrenergic receptor
Molecular Weight
43518.615 Da
References
  1. Feve B, Emorine LJ, Lasnier F, Blin N, Baude B, Nahmias C, Strosberg AD, Pairault J: Atypical beta-adrenergic receptor in 3T3-F442A adipocytes. Pharmacological and molecular relationship with the human beta 3-adrenergic receptor. J Biol Chem. 1991 Oct 25;266(30):20329-36. [PubMed:1682311]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Dudley AJ, Bleasby K, Brown CD: The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000 Sep;131(1):71-9. [PubMed:10960071]

Drug created on August 29, 2007 08:53 / Updated on December 01, 2017 17:19